Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas

Abstract

Recent studies claim a critical role for RUNX3 in gastric epithelial homeostasis. However, conflicting results exist regarding RUNX3 expression in the stomach and its potential role as a tumour-suppressor gene (TSG) in gastric carcinogenesis. Our aim was to evaluate the role of RUNX3 in early-onset gastric carcinomas (EOGCs). We analysed 41 EOGCs for RUNX3 aberrations using loss of heterozygosity (LOH), fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) analyses. LOH of markers flanking RUNX3 was relatively common, indicating that loss of the gene may play a role in gastric carcinogenesis. However, FISH analysis of selected cases and a panel of 14 gastric carcinoma-derived cell lines showed widespread presence of multiple copies of centromere 1. While RUNX3 copy numbers were generally equal to or fewer than those of centromere 1, at least two copies were present in almost all cells analysed. Accordingly, a subpopulation of tumour cells in 12/37 cases showed RUNX3 protein expression. However, expression was not detected in the adjacent nontumorous mucosa of any case. Together, these observations indicate that chromosome 1 aberrations occur frequently in EOGCs and are reflected in the LOH and IHC patterns found. Our findings refute a role for RUNX3 as a TSG in EOGCs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  • Bae SC and Choi JK . (2004). Oncogene, 23, 4336–4340.

  • Bangsow C, Rubins N, Glusman G, Bernstein Y, Negreanu V, Goldenberg D, Lotem J, Ben-Asher E, Lancet D, Levanon D and Groner Y . (2001). Gene, 279, 221–232.

  • Brenner O, Levanon D, Negreanu V, Golubkov O, Fainaru O, Woolf E and Groner Y . (2004). Proc. Natl. Acad. Sci. USA, 101, 16016–16021.

  • Carvalho R, Milne AN, van Rees BP, Caspers E, Cirnes L, Figueiredo C, Offerhaus GJ and Weterman MA . (2004). J. Pathol., 204, 75–83.

  • Corver WE, Ter Haar NT, Dreef EJ, Miranda NF, Prins FA, Jordanova ES, Cornelisse CJ and Fleuren GJ . (2005). J. Pathol., 206, 233–241.

  • Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP and Bouck N . (1998). Cell, 93, 1159–1170.

  • Ehlers M, Laule-Kilian K, Petter M, Aldrian CJ, Grueter B, Wurch A, Yoshida N, Watanabe T, Satake M and Steimle V . (2003). J. Immunol., 171, 3594–3604.

  • Etoh T, Kanai Y, Ushijima S, Nakagawa T, Nakanishi Y, Sasako M, Kitano S and Hirohashi S . (2004). Am. J. Pathol., 164, 689–699.

  • Fainaru O, Woolf E, Lotem J, Yarmus M, Brenner O, Goldenberg D, Negreanu V, Bernstein Y, Levanon D, Jung S and Groner Y . (2004). EMBO J., 23, 969–979.

  • Fernandez-Salguero PM, Ward JM, Sundberg JP and Gonzalez FJ . (1997). Vet. Pathol., 34, 605–614.

  • Fukamachi H and Ito K . (2004). Oncogene, 23, 4330–4335.

  • Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Stavnezer J, Kawabata M, Miyazono K and Ito Y . (1999). J. Biol. Chem., 274, 31577–31582.

  • Haralambieva E, Kleiverda K, Mason DY, Schuuring E and Kluin PM . (2002). J. Pathol., 198, 163–170.

  • Igarashi J, Nimura Y, Fujimori M, Mihara M, Adachi W, Kageyama H and Nakagawara A . (2000). Jpn. J. Cancer Res., 91, 797–801.

  • Inoue K, Ozaki S, Shiga T, Ito K, Masuda T, Okado N, Iseda T, Kawaguchi S, Ogawa M, Bae SC, Yamashita N, Itohara S, Kudo N and Ito Y . (2002). Nat. Neurosci., 5, 946–954.

  • Ito Y and Miyazono K . (2003). Curr. Opin. Genet. Dev., 13, 43–47.

  • Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA, Howe HL, Anderson RN and Edwards BK . (2004). Cancer, 101, 3–27.

  • Kokkola A, Monni O, Puolakkainen P, Nordling S, Haapiainen R, Kivilaakso E and Knuutila S . (1998). Cancer Genet. Cytogenet., 107, 32–36.

  • Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S and Kishimoto T . (1997). Cell, 89, 755–764.

  • Le XF, Groner Y, Kornblau SM, Gu Y, Hittelman WN, Levanon D, Mehta K, Arlinghaus RB and Chang KS . (1999). J. Biol. Chem., 274, 21651–21658.

  • Lee B, Thirunavukkarasu K, Zhou L, Pastore L, Baldini A, Hecht J, Geoffroy V, Ducy P and Karsenty G . (1997). Nat. Genet., 16, 307–310.

  • Levanon D, Bettoun D, Harris-Cerruti C, Woolf E, Negreanu V, Eilam R, Bernstein Y, Goldenberg D, Xiao C, Fliegauf M, Kremer E, Otto F, Brenner O, Lev-Tov A and Groner Y . (2002). EMBO J., 21, 3454–3463.

  • Levanon D, Brenner O, Negreanu V, Bettoun D, Woolf E, Eilam R, Lotem J, Gat U, Otto F, Speck N and Groner Y . (2001). Mech Dev., 109, 413–417.

  • Levanon D, Brenner O, Otto F and Groner Y . (2003). EMBO Rep., 4, 560–564.

  • Levanon D and Groner Y . (2004). Oncogene, 23, 4211–4219.

  • Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC and Ito Y . (2002). Cell, 109, 113–124.

  • Miki R, Okuda M, Oikawa T, Watanabe M, Ma Z, Matsumoto K, Iwata H and Inokuma H . (2004). J. Vet. Med. Sci., 66, 797–805.

  • Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU and Olsen BR . (1997). Cell, 89, 773–779.

  • Okuda T, van Deursen J, Hiebert SW, Grosveld G and Downing JR . (1996). Cell, 84, 321–330.

  • Osaki M, Moriyama M, Adachi K, Nakada C, Takeda A, Inoue Y, Adachi H, Sato K, Oshimura M and Ito H . (2004). Eur. J. Clin. Invest., 34, 605–612.

  • Parkin DM, Pisani P and Ferlay J . (1999). Int. J. Cancer, 80, 827–841.

  • Sakakura C, Mori T, Sakabe T, Ariyama Y, Shinomiya T, Date K, Hagiwara A, Yamaguchi T, Takahashi T, Nakamura Y, Abe T and Inazawa J . (1999). Genes Chromosomes Cancer, 24, 299–305.

  • Sano T, Tsujino T, Yoshida K, Nakayama H, Haruma K, Ito H, Nakamura Y, Kajiyama G and Tahara E . (1991). Cancer Res., 51, 2926–2931.

  • Tanaka K, Yanoshita R, Konishi M, Oshimura M, Maeda Y, Mori T and Miyaki M . (1993). Oncogene, 8, 2253–2258.

  • Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T, Ito Y and Littman DR . (2002). Cell, 111, 621–633.

  • Varis A, van Rees B, Weterman M, Ristimaki A, Offerhaus J and Knuutila S . (2003). Br. J. Cancer, 88, 1914–1919.

  • Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, Brenner O, Berke G, Levanon D and Groner Y . (2003). Proc. Natl. Acad. Sci. USA, 100, 7731–7736.

  • Wu CW, Chen GD, Fann CS, Lee AF, Chi CW, Liu JM, Weier U and Chen JY . (2002). Genes Chromosomes Cancer, 35, 219–231.

Download references

Acknowledgements

We thank Dr D Levanon and Dr Y Groner (The Weizmann Institute of Science, Israel) for the invaluable assistance with RUNX3 IHC detection and analysis. We also thank Alex Musler, Folkert Morsink, Monique Oud and Esther Schilder (Academisch Medisch Centrum, The Netherlands) for the technical assistance provided. We further wish to acknowledge Dr S Akiyama (Nagoya University School of Medicine, Japan), Dr JN Primrose (Southampton General Hospital, UK), Dr H Yokozaki (Hiroshima University School of Medicine, Japan), Professor T Suzuki (Fukushima Medical College, Japan), Dr K Yanagihara (National Cancer Centre Research Institute, Japan), Dr M Manns (Medizinische Hochschule Hannover, Germany), Dr A van der Ende (Academisch Medisch Centrum, The Netherlands) and Professor M Sobrinho-Simões (Instituto de Patologia e Imunologia Molecular da Universidade do Porto, Portugal) for kindly providing the cell lines used in this study. Finally, we wish to thank Dr A Varis and Dr S Knuutila (both from the University of Helsinki, Finland) for their FISH expertise and their many helpful suggestions. This work was supported by the Vanderes Foundation, grant 68.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ralph Carvalho.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carvalho, R., Milne, A., Polak, M. et al. Exclusion of RUNX3 as a tumour-suppressor gene in early-onset gastric carcinomas. Oncogene 24, 8252–8258 (2005). https://doi.org/10.1038/sj.onc.1208963

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208963

Keywords

This article is cited by

Search

Quick links